MCID: AVD001
MIFTS: 49

Avoidant Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Avoidant Personality Disorder

MalaCards integrated aliases for Avoidant Personality Disorder:

Name: Avoidant Personality Disorder 12 73 15 70
Anxious Personality Disorder 12 70
Personality Disorders 44 70

Classifications:



External Ids:

Disease Ontology 12 DOID:1509
ICD9CM 34 301.82
MeSH 44 D010554
NCIt 50 C92636
SNOMED-CT 67 191771004
ICD10 32 F60.6
UMLS 70 C0004444 C0031212 C0494415

Summaries for Avoidant Personality Disorder

Disease Ontology : 12 A personality disorder that is characterized by a pervasive pattern of social inhibition, feelings of inadequacy, extreme sensitivity to negative evaluation, and avoidance of social interaction.

MalaCards based summary : Avoidant Personality Disorder, also known as anxious personality disorder, is related to major depressive disorder and disease of mental health, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Avoidant Personality Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Salivary secretion and Galactose metabolism. The drugs Lamotrigine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and temporal lobe, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Avoidant personality disorder (AvPD) is a Cluster C personality disorder in which the main coping... more...

Related Diseases for Avoidant Personality Disorder

Diseases related to Avoidant Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 196)
# Related Disease Score Top Affiliating Genes
1 major depressive disorder 29.7 MAOA AMY1C AMY1B AMY1A
2 disease of mental health 29.2 SRGAP3 SRGAP2 MAOA AMY1C AMY1B AMY1A
3 personality disorder 11.1
4 multiple personality disorder 11.0
5 dystonia 11, myoclonic 10.9
6 digeorge syndrome 10.9
7 ceroid lipofuscinosis, neuronal, 8 10.9
8 ceroid lipofuscinosis, neuronal, 7 10.9
9 dissociative seizures 10.9
10 gardner-diamond syndrome 10.9
11 social phobia 10.9
12 antisocial personality disorder 10.8
13 anxiety 10.6
14 paranoid personality disorder 10.6
15 narcissistic personality disorder 10.5
16 borderline personality disorder 10.5
17 bipolar disorder 10.5
18 major affective disorder 8 10.5
19 major affective disorder 9 10.5
20 anorexia nervosa 10.5
21 eating disorder 10.5
22 dysthymic disorder 10.4
23 psychotic disorder 10.4
24 conduct disorder 10.4
25 generalized anxiety disorder 10.4
26 schizophrenia 10.4
27 substance abuse 10.3
28 severe combined immunodeficiency 10.3
29 cocaine dependence 10.3
30 somatization disorder 10.3
31 tobacco addiction 10.3
32 smoking as a quantitative trait locus 3 10.3
33 pathological gambling 10.3
34 acute stress disorder 10.3
35 drug dependence 10.3
36 endogenous depression 10.2
37 adjustment disorder 10.2
38 bulimia nervosa 10.2
39 schizotypal personality disorder 10.2
40 obsessive-compulsive personality disorder 10.2
41 mental depression 10.2
42 neurotic disorder 10.2
43 hypochondriasis 10.2
44 epilepsy 10.1
45 temporal lobe epilepsy 10.1
46 schizoaffective disorder 10.1
47 postpartum depression 10.1
48 alacrima, achalasia, and mental retardation syndrome 10.1
49 autism spectrum disorder 10.1
50 melancholia 10.1

Comorbidity relations with Avoidant Personality Disorder via Phenotypic Disease Network (PDN):


Dependent Personality Disorder Dysthymic Disorder
Major Depressive Disorder

Graphical network of the top 20 diseases related to Avoidant Personality Disorder:



Diseases related to Avoidant Personality Disorder

Symptoms & Phenotypes for Avoidant Personality Disorder

UMLS symptoms related to Avoidant Personality Disorder:


photophobia; restlessness; personality changes; pseudobulbar behavioral symptoms; sleep disturbances

GenomeRNAi Phenotypes related to Avoidant Personality Disorder according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-105 10.46 AMY1A AMY1B AMY1C
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-11 10.46 SRGAP2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.46 AMY1A AMY1B AMY1C
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.46 AMY1A AMY1B AMY1C
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 10.46 SRGAP2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-56 10.46 SRGAP2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 10.46 AMY1A AMY1B AMY1C
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-96 10.46 SRGAP2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.28 AMY1A AMY1B AMY1C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.28 AMY1A AMY1B AMY1C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.28 AMY1A AMY1B AMY1C

Drugs & Therapeutics for Avoidant Personality Disorder

Drugs for Avoidant Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
2
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
3
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
4
Naratriptan Approved, Investigational Phase 4 143388-64-1, 121679-13-8 4440
5 Sodium Channel Blockers Phase 4
6 Diuretics, Potassium Sparing Phase 4
7 calcium channel blockers Phase 4
8 Calcium, Dietary Phase 4
9 Dopamine Antagonists Phase 4
10 Adrenergic alpha-Agonists Phase 4
11 Adrenergic Agonists Phase 4
12 Neurotransmitter Agents Phase 4
13 Adrenergic Agents Phase 4
14 Antihypertensive Agents Phase 4
15 Vasoconstrictor Agents Phase 4
16 Serotonin 5-HT1 Receptor Agonists Phase 4
17 Serotonin Receptor Agonists Phase 4
18
Calcium Nutraceutical Phase 4 7440-70-2 271
19
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
20
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
21
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585 135398745
22
Fluoxetine Approved, Vet_approved Phase 3 54910-89-3 3386
23
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
24 Monoamine Oxidase Inhibitors Phase 3
25 Neuroprotective Agents Phase 3
26 Antiparkinson Agents Phase 3
27 Quetiapine Fumarate Phase 3 111974-72-2
28 Gastrointestinal Agents Phase 3
29 Antiemetics Phase 3
30 Psychotropic Drugs Phase 3
31 Serotonin Uptake Inhibitors Phase 3
32 Antidepressive Agents Phase 3
33 Cytochrome P-450 Enzyme Inhibitors Phase 3
34 Narcotics Phase 3
35 Narcotic Antagonists Phase 3
36 Analgesics, Opioid Phase 3
37
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
38
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
39
Acetaminophen Approved Phase 2 103-90-2 1983
40
Ziprasidone Approved Phase 2 146939-27-7 60854
41
Lithium carbonate Approved Phase 2 554-13-2
42
Ketamine Approved, Vet_approved Phase 2 6740-88-1 3821
43
Midazolam Approved, Illicit Phase 2 59467-70-8 4192
44
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
45
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
46
Brexpiprazole Approved, Investigational Phase 2 913611-97-9 11978813
47
Citalopram Approved Phase 2 59729-33-8 2771
48
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
49
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
50
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032

Interventional clinical trials:

(show top 50) (show all 263)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
3 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
4 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
5 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
6 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS) Completed NCT00204347 Phase 4 risperidone
7 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
8 Pharmacology of Cognition in Schizotypal Personality Disorder: Guanfacine for Cognitive Symptoms in Schizotypal Personality Disorder Terminated NCT00353379 Phase 4 Guanfacine;Placebo
9 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
10 BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder Completed NCT00538135 Phase 3
11 A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
12 Seroquel XR for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
13 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo Completed NCT00088036 Phase 3 Olanzapine
14 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
15 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo Completed NCT00091650 Phase 3 Olanzapine;placebo
16 First Experimental Study of Transference Interpretations (FEST) Completed NCT00423462 Phase 2, Phase 3
17 A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder Recruiting NCT04186403 Phase 2, Phase 3 Brexpiprazole
18 Short-term Versus Long-term Mentalization-based Therapy for Outpatients With Subthreshold or Diagnosed Borderline Personality Disorder: a Randomized Clinical Trial Active, not recruiting NCT03677037 Phase 3
19 Staged Treatment in Early Psychosis (STEP): A Sequential Multistage Randomized Clinical Trial (SMART) of Interventions for Ultra High Risk (UHR) of Psychosis Patients. Active, not recruiting NCT02751632 Phase 3 Fluoxetine;Placebo
20 Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder Terminated NCT00124839 Phase 3 Naltrexone
21 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
22 Acetaminophen and Social Pain in Borderline Personality Disorder Unknown status NCT02108990 Phase 2 Acetaminophen
23 Multimodal Study of the Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder : Stress Reactivity and Functional Imaging Unknown status NCT03209102 Phase 2
24 Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder Unknown status NCT01466205 Phase 2 DAR-0100A;Placebo
25 A Randomized Controlled Study of the Efficacy of Analytic Oriented Group Psychotherapy for Psychiatric Outpatients Unknown status NCT00521417 Phase 2
26 ENGAGE - Meeting Mental Health Needs of Complex Comorbid Patients Attending A&E Following a Suicide Attempt. A Pilot Study. Unknown status NCT00980824 Phase 1, Phase 2
27 A Randomised Controlled Trial of Imagery Rehearsal Therapy (IRT) of Nightmares in a Psychiatric Population Completed NCT00291031 Phase 1, Phase 2
28 Schizotypal Personality Disorder Risperidone Completed NCT02535156 Phase 1, Phase 2 Risperidone;Placebo
29 A D1 Agonist For Working Memory Enhancement In The Schizophrenia Spectrum Completed NCT02507206 Phase 2 DAR 0-100A;Placebo
30 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
31 Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study Completed NCT00635921 Phase 2 ziprasidone;Placebo
32 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Completed NCT02728778 Phase 2 incobotulinumtoxin A
33 Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum Completed NCT02524899 Phase 2 Guanfacine;Placebo
34 Psychodynamic Therapy for Patients With Borderline Personality Disorder and Alcohol Abuse Completed NCT00145678 Phase 2
35 The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial Completed NCT00254748 Phase 2 Quetiapine fumarate;Placebo
36 Assessment and Treatment of Parasuicidal Patients Completed NCT00183651 Phase 2
37 Treatment of Bulimia Nervosa: Dysregulated Subtype Completed NCT00494858 Phase 2
38 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
39 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
40 A Randomized Active Placebo Controlled Trial of Ketamine in Borderline Personality Disorder Recruiting NCT03395314 Phase 2 Ketamine;Midazolam
41 A Phase II Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 1358894 Once Daily Over 12 Week Treatment Period in Patients With Borderline Personality Disorder Recruiting NCT04566601 Phase 2 BI 1358894;Placebo
42 A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct in Patients With Borderline Personality Disorder Recruiting NCT02097706 Phase 2 NMDA receptor antagonist (active drug)
43 Investigating the Impact of Oxytocin on Irritability/Emotional Dysregulation in Children and Adolescents With Disruptive Behavior and Mood Disorders, and the Possible Mediating Role of Amygdala Activity Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
44 A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder. Active, not recruiting NCT03418675 Phase 2 Rexulti;Placebo
45 A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder Active, not recruiting NCT04100096 Phase 2 Brexpiprazole
46 SSRIs and Self-harm in Borderline Personality Disorder Terminated NCT01103180 Phase 2 Escitalopram
47 Preliminary, Double Blind, Placebo Controlled Trial of the Effect of Glucocorticoid Receptor Antagonist Treatment on Biologic and Symptom Outcomes in Patients With Borderline Personality Disorder and Histories of Childhood Abuse Terminated NCT01212588 Phase 2 mifepristone;Placebo
48 A Double-Blind, Placebo-controlled Pilot Study of NAC Addition to Dialectical Behavioral Therapy for the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder Terminated NCT00539188 Phase 2 N-Acetylcysteine;placebo
49 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
50 Study of Outcome With an Intervention From the Cape Cod Model of Psychotherapy for Subjects in a Behavioral Crisis and With the Diagnosis of Borderline Personality Disorder (BPD) or Post-Traumatic Stress Disorder (PTSD) Unknown status NCT00269139 Phase 1

Search NIH Clinical Center for Avoidant Personality Disorder

Cochrane evidence based reviews: personality disorders

Genetic Tests for Avoidant Personality Disorder

Anatomical Context for Avoidant Personality Disorder

MalaCards organs/tissues related to Avoidant Personality Disorder:

40
Brain, Cortex, Temporal Lobe, Eye, Amygdala, Heart, Skin

Publications for Avoidant Personality Disorder

Articles related to Avoidant Personality Disorder:

(show top 50) (show all 8765)
# Title Authors PMID Year
1
Differential psychopathological profile of male intimate partner violence perpetrators depending on Problematic alcohol use. 61
33714033 2021
2
Substance use among patients in specialized mental health services in Norway: prevalence and patient characteristics based on a national census. 61
32945698 2021
3
Current rodent models for the study of empathic processes. 61
33136617 2021
4
Is There a Bias in the Diagnosis of Borderline Personality Disorder Among Lesbian, Gay, and Bisexual Patients? 61
32981328 2021
5
Unraveling the Personality Profile of the Sexual Murderer. 61
29783916 2021
6
Alternative DSM-5 Model for Personality Disorders Through the Lens of an Empirical Network Model. 61
31928067 2021
7
A Plea for Preregistration in Personality Disorders Research: The Case of Psychopathy. 61
30920938 2021
8
Personality Disorders in the ICD-11: Spanish Validation of the PiCD and the SASPD in a Mixed Community and Clinical Sample. 61
32583685 2021
9
Personality, Schizophrenia, and Violence: A Longitudinal Study: The Second Wave of the VIORMED Project. 61
31609185 2021
10
Changing Outdated Methadone Regulations That Harm Pregnant Patients. 61
32826620 2021
11
Childhood trauma determines different clinical and biological manifestations in patients with eating disorders. 61
32424563 2021
12
Avoidable emergency department presentations for dental comorbidities of psychiatric disorders: A population-based record-linkage analysis. 61
33611073 2021
13
Psychiatric comorbidities in patients with psychogenic nonepileptic seizures. 61
33735815 2021
14
Lifetime psychiatric hospital diagnoses among 8,412 Danish men registered in an outpatient alcohol clinic. 61
33421359 2021
15
Various mentalizing concepts in mothers with postpartum depression, comorbid anxiety, and personality disorders. 61
33759190 2021
16
Anxiety and Depression: A Key to Understanding the Complete Expression of Personality Disorders. 61
33273394 2021
17
Comorbid personality difficulties are not associated with poorer outcomes for online cognitive behaviour therapy for symptoms of anxiety and depression. 61
33650772 2021
18
Childhood sexual abuse in patients with severe mental Illness: demographic, clinical and functional correlates. 61
33779997 2021
19
Personality disorder among youth with first episode psychotic mania: An important target for specific treatment? 61
33768702 2021
20
Interpersonal Problems in Parents and Adolescent Borderline Personality Disorder Features. 61
33764823 2021
21
Themes of the dark core of personality. 61
33779194 2021
22
Commentary about social avoidance and its significance in adolescents and young adults. 61
33465524 2021
23
First episode psychosis: register-based study of comorbid psychiatric disorders and medications before and after. 61
32458108 2021
24
Personality in Combination with Alcohol and Drug Use and Psychiatric Disorders to Predict Psychosocial Characteristics and Behaviors of Hepatitis C Patients. 61
31907744 2021
25
Personality Disorders as a Basis for Discharge and Denial of Benefits in the Military: Logical or Abusive? 61
33620913 2021
26
Total and cause-specific mortality in patients with personality disorders: the association between comorbid severe mental illness and substance use disorders. 61
33677644 2021
27
Is pharmacotherapy useful for treating personality disorders? 61
33432834 2021
28
Moving in together, marriage, and motherhood: A follow up study of relationships in psychiatric patients with personality disorders. 61
33660390 2021
29
Do comorbid personality disorders in cocaine dependence exacerbate neuroanatomical alterations? A structural neuroimaging study. 61
33716043 2021
30
The longitudinal impact of DSM-5 Section III specific personality disorders on relationship satisfaction. 61
32730061 2021
31
The effectiveness of adapted schema therapy for cluster C personality disorders in older adults - integrating positive schemas. 61
33604483 2021
32
Exploring differences in quality of life in clinical populations of depressed outpatients with and without personality disorders. 61
33601687 2021
33
Is Home Treatment for Everyone? Characteristics of Patients Receiving Intensive Mental Health Care at Home. 61
33735397 2021
34
A Multi-Method Investigation of Normative and Pathological Personality Across the Spectrum of Gambling Involvement. 61
33655450 2021
35
Interdisciplinarity and Integration: An Introduction to the Special Issue on Psychopathology in Medical Settings. 61
33219478 2021
36
Measuring Behavioral Inhibition and Behavioral Activation in Older Adults: Construct Validity of the Dutch BIS/BAS Scales. 61
33736472 2021
37
Maternal Mental Disorders and Pediatric Infectious Diseases: A Retrospective Cohort Study. 61
33657596 2021
38
Predicting smoking and nicotine dependence from the DSM-5 alternative model for personality pathology. 61
33705195 2021
39
The relation of major depression, OCD, personality disorders and affective temperaments with Temporal lobe epilepsy. 61
33535159 2021
40
Emotional abuse interacts with borderline personality in adolescent inpatients with binge-purging eating disorders. 61
33677816 2021
41
Schema therapy with exposure and response prevention for the treatment of chronic anxiety with comorbid personality disorder. 61
33319395 2021
42
Structural brain alterations in young adult males with narcissistic personality disorder: a diffusion tensor imaging study. 61
33635732 2021
43
Obsessive-Compulsive Personality Disorder Co-occurring in Individuals with Obsessive-Compulsive Disorder: A Systematic Review and Meta-analysis. 61
33666394 2021
44
Transdiagnostic perspective on psychological inflexibility and emotional dysregulation. 61
32895066 2021
45
Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program. 61
33713298 2021
46
Predictors of Patients' Responses to Spiritual Psychotherapy for Inpatient, Residential, and Intensive Treatment (SPIRIT). 61
33691486 2021
47
Assessing Self-Definition and Relatedness in Level of Personality Functioning. 61
33764821 2021
48
Severity Indices of Personality Problems-Short Form in Old-Age Psychiatry: Reliability and Validity. 61
32267173 2021
49
Association of Wender Utah Rating Scale (WURS)-61 items with clinical psychiatric diagnosis in adulthood. 61
33665779 2021
50
[The German Version of the Level of Personality Functioning Scale-Brief Form 2.0 (LPFS-BF): Latent Structure, Convergent Validity and Norm Values in the General Population]. 61
33694153 2021

Variations for Avoidant Personality Disorder

Expression for Avoidant Personality Disorder

Search GEO for disease gene expression data for Avoidant Personality Disorder.

Pathways for Avoidant Personality Disorder

GO Terms for Avoidant Personality Disorder

Biological processes related to Avoidant Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate metabolic process GO:0005975 9.13 AMY1C AMY1B AMY1A
2 oligosaccharide metabolic process GO:0009311 8.8 AMY1C AMY1B AMY1A

Molecular functions related to Avoidant Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cation binding GO:0043169 9.43 AMY1C AMY1B AMY1A
2 chloride ion binding GO:0031404 9.33 AMY1C AMY1B AMY1A
3 alpha-amylase activity (releasing maltohexaose) GO:0103025 9.13 AMY1C AMY1B AMY1A
4 alpha-amylase activity GO:0004556 8.8 AMY1C AMY1B AMY1A

Sources for Avoidant Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....